10x Genomics signals 5% sequential revenue growth for Q4 2025 as new product launches drive adoption

Discover key Q3 2025 earnings insights for 10x Genomics (TXG): revenue growth, new product launches, and Q4 outlook.
The American Journal of Managed Care

Sequencing Therapies and Using the Most Effective Options First

Panelists discuss how sequencing decisions favor early use of the most potent therapies to extend survival in EGFR-positive ...